Prognostic value of immunological profile based on CD8+ and FoxP3+ T lymphocytes in the peritumoral and intratumoral subsites for renal cell carcinoma

Purpose We aimed to assess an “Immunological Profile (IP)” including CD8+ and FoxP3+ T lymphocytes for renal cell carcinoma (RCC) to evaluate its effects on tumor pathological characteristics, disease progression, and survival. Methods Adjacent normal and intratumoral specimens from 42 patients who...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2020-12, Vol.52 (12), p.2289-2299
Main Authors: Teke, Kerem, Yaprak Bayrak, Busra, Yuksekkaya, Mustafa, Uslubas, Ali Kemal, Kosem, Mehmet Esat, Yilmaz, Hasan, Kara, Onder, Dillioglugil, Ozdal
Format: Article
Language:English
Subjects:
CD8 antigen
Foxp3 protein
Immunohistochemistry
Immunology
Kidney cancer
Lymph nodes
Lymphocytes
Lymphocytes T
Medicine
Medicine & Public Health
Metastases
Nephrectomy
Nephrology
Renal cell carcinoma
Urology
Urology - Original Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose We aimed to assess an “Immunological Profile (IP)” including CD8+ and FoxP3+ T lymphocytes for renal cell carcinoma (RCC) to evaluate its effects on tumor pathological characteristics, disease progression, and survival. Methods Adjacent normal and intratumoral specimens from 42 patients who had undergone radical nephrectomy for RCC were analyzed for counts of CD8+ and FoxP3+ T lymphocytes by immunohistochemistry. Tissue from both sites were evaluated and scored separately according to low (0) or high (1) expression of CD8 and FoxP3. A total score (min: 0, max: 4) was assigned to each patient. Thereafter, patients were divided into two groups for clinicopathologic and survival stratification based on score (IP Weak 0–2; and IP Strong 3–4). Survival curves were constructed using the Kaplan–Meier method, and a multivariable Cox regression model was used for overall survival (OS) and progression-free survival (PFS). Results The mean follow-up was 54.73 ± 21.34 months. Poor RCC characteristics including pT3–T4, tumor necrosis, lymphovascular invasion, lymph node involvement, and larger tumor size were significantly more common in the IP Weak patients compared to IP Strong ( p  
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-020-02592-x